STOCKS TELEGRAPH

Author: Muhammad Ali

  • Exela Technologies, Inc. (XELA) stock rises in Premarket: Here’s Why

    Exela Technologies, Inc. (XELA) stock rises in Premarket: Here’s Why

    Shares of the Exela Technologies, Inc. (XELA) stock were rising in the premarket trading session today on January 13, 2022. XELA stock price saw a push of 2.37% to reach $0.61 a share at the time of this writing. The stock was gloomy in the previous trading session and went down by 7.12% at closing. Let’s understand the reason behind this rise.

    What’s Happening?

    XELA stock happened to be green in the premarket after the company announced that it has expanded its existing relationships with Mastercard in the EMEA region. This expansion will result in the automation of Giro payments and processing in Norway via using the XBP platform of Exela.

    The company will automate the content extraction of payment documents in the Brevgiro service in Norway via developing and deploying an innovative solution using optical/intelligent character reading. The payment transactions will be verified automatically through this solution. More than 11 million Giro payments in Norway will use this solution.

    Previous News of XELA stock

    A couple of days ago, on January 11, 2022, the company reported that it is expanding its relationships with leading health insurance organizations. The consumer will continue to deploy the PCH Global platform of Exela in order to accelerate its digital transformation and improve the provider and member experience. The expansion represents the $6.2 million of additional contract value revenue.

    Financial View of XELA stock

    • In the third quarter of 2021, the company generated $279.2 million in revenue as compared to $305.3 million in the same quarter of last year. This represents an 8.5% decline as compared to the previous year’s same quarter results.
    • Operating income in the third quarter of 2021 for the XELA stock was $2.4 million. This compares to an operating income of $4.8 million in the same tenure of the previous year.
    • XELA stock suffered a net loss of $13.2 million in the third quarter of 2021 as compared to a net loss of $28.3 million in the same quarter of last year.
    • EBITDA for the company was $49.1 million while the adjusted EBITDA was $36.4 million in the third quarter of 2021.
    • By the end of the third quarter of 2021, there were 166,196,745 outstanding shares along with additional shares of common XELA stock.

    Wrap Up

    The company is expanding its existing relationships which represents that the company is progressing with time. This is indeed a positive sign for the company as well shareholders of the XELA stock. However, the financial results reflect that the company’s revenue declined in the recent quarter. In a nutshell, investors need to do deep research before adding this stock to their portfolio.

  • IAMGOLD Corporation (IAG) stock declines in Current Market: Here’s Why

    IAMGOLD Corporation (IAG) stock declines in Current Market: Here’s Why

    Shares of the IAMGOLD Corporation (IAG) stock were declining in the current market trading session today on January 12, 2022. IAG stock price saw a decline of 4.58% to drop at $2.82 a share at the time of this writing. The trading volume on the last check was 1,982,052, lower than the average trading volume. Let’s deep dive to understand the reason behind this rise.

    Fourth Quarter and Full-Year Operational Results of IAG

    • IAG stock became bearish after the company announced the fourth quarter and full-year 2021 operational results and provided a 2022 operational outlook. Gold production in the year 2021 was 601,000 ounces of the company. In the fourth quarter, the company produced 153,000 ounces of gold.
    • The company reported $1.2 billion approximate revenue based on 590,000 ounces of gold sales. In the fourth quarter of 2021, revenues reached $295 million based on 152,000 ounces of gold sales.
    • The company produced 412,000 ounces of gold in 2021. This means that the gold production exceeded the upper limit of the previously guided range of 390,000 to 400,000 ounces
    • For Rosebel, the annual gold production was 154,000 ounces, near to the upper guidance range of 160,000 ounces. The attributable production in the fourth quarter was 42,000 ounces for the IAG stock.
    • For Westwood, the gold production was 35,000 ounces, equal to the lower guidance of  35,000 In the fourth quarter of 2021, the guidance range was 35,000.

    2022 Outlook of IAG stock

    • IAG expects that the gold production for 2022 will be in the range of 570,000 to 640,000 ounces.
    • The company estimated the cash costs between $1,100 and $1,150 per ounce sold for the year 2022.

    Financial Expectations

    IAMGOLD Corporation expects consolidated cash costs in the range of $1,115 and $1,150 per ounce sold in 2021.  consolidated AISC will be between $1,395 and $1,435 per ounce sold. The company is optimistic that its capital expenses will be in line with the expectations of the company. The company ended the fourth quarter and year 2021 with $545 million in cash and cash equivalents. The company had restricted cash of $42 million and short-term investments of $8 million by the end of the year 2021.

    Wrap Up

    It seems that investors did not like the operational results for the fourth quarter and full-year 2021 of the IAG stock. Investors eyeing this stock need to do deep research before making any decision.

  • Why Ginkgo Bioworks Holdings, Inc. (DNA) stock is declining today?

    Why Ginkgo Bioworks Holdings, Inc. (DNA) stock is declining today?

    Shares of the Ginkgo Bioworks Holdings, Inc. (DNA) stock were declining in the current market today on January 12, 2022. The stock became bearish after the company provided the update regarding its preliminary unaudited 2021 revenue highlights and business review. DNA stock price saw a decline of 1.76% to reach $6.71 a share at the time of this writing. Let’s deep dive to explore more of it.

    Recent Update of the DNA stock:

    • The company has reported today that it expects to meet or exceed the revenue targets for the full year 2021. The company expects that its revenue from its cell programming and biosecurity offerings will be more than estimated. Ginkgo is anticipating that its Biosecurity revenue will exceed its previous outlook by 50%. The 2021 key performance highlights are given below.
    • The company completed its goal of adding at least 30 new programs in 2021. This milestone resulted in the launch of 100 cumulative cell programs at Ginkgo.
    • The company previously provided the estimate of $100 million Foundry revenue for the full year 2021. DNA expects higher revenue than the previously provided outlook for the full year 2021.
    • The Biosecurity revenue is expected to increase by more than 50% from the previously disclosed outlook by the company. The previous outlook for the revenue of DNA stock was $110 million.

    2022 Priorities:

    Ginkgo Bioworks has a strong balance sheet, and the management is optimistic that the company will outperform in the future. The main focus of the company in 2022 is to invest in the platform infrastructure and research and development. The management is also focusing on the organization buildout in order to support scaling partnerships. Opportunistic external investments are also included in the list of 2022 priorities of the company.

    Previous News of DNA stock:

    Recently Ginkgo Bioworks adopted the Onyx™ genome engineering platform in its foundries. Ginkgo is committed to integrating cutting-edge technology into its foundries. The motive behind this is to leverage the performance as well as productivity of the metabolic and engineering workflow of the company. The company is progressing which is a good sign for the long-term shareholders of the DNA stock.

    Conclusion:

    DNA stock has captivated the attention of the investors after the company provided the business review and highlights. However, the stock has lost 30.56% in the last thirty days and almost 30% in the last six months.

  • Hyzon Motors Inc. (HYZN) stock is Gloomy in Premarket: Here’s Why

    Hyzon Motors Inc. (HYZN) stock is Gloomy in Premarket: Here’s Why

    Shares of the Hyzon Motors Inc. (HYZN) stock were gloomy in the premarket trading session today on January 12, 2022. HYZN stock price saw a downtrend of 14.10% to drop at $5.85 a share at the time of this writing. The stock was green in the previous trading session and went up by 8.86% at closing. Let’s understand the reason behind this fall.

    What’s Happening?

    HYZN stock became bearish after Hyzon Motors provided the financial outlook and 2021 delivery update. The company has delivered 87 fuel cell-powered heavy-duty vehicles in the year 2021 under the commercial sales agreement. Trial leases are not part of these deliveries.

    The estimated shipments in 2021 were 85, which means the shipments exceeded the expectations in 2021. However, the company is expecting lower than forecasted revenues and margins in the upcoming financial results. Lower revenues and margins are due to the lower average selling price per vehicle. the company anticipates that the product mix and multi-year revenue recognition for most of the sales will lead to lower revenues and margins. In the third quarter of 2021, the deployment focus of the company was Asia, where the average selling prices were less than the other regions. Shareholders of the HYZN stock after hearing this news responded negatively which resulted in the decline in the per-share price of this stock.

    Previous News of HYZN stock

    On December 21, 2021, -Bragar Eagel & Squire, P.C. announced that it has started investigations against Hyzon on the behalf of long-term shareholders of HYZN stock. The investigations concerned the potential claims of breaching fiduciary duties against Hyzon motors and its board of directors. The class action complaint alleged the defendants for misleading statements and hiding the facts about the company’s operations, business and prospects.

    Contract with Geesinknorba Group

    On December 16, 2021, HYZN announced that it has signed the agreement with Geesinknorba. According to the agreement, Hyzon is now the exclusive vendor for the zero-emission trucks of Geesinknorba. Within the duration of three years, 300 or more trucks will be supplied to Europe by Hyzon under this contract. This partnership is beneficial for the growth of both companies as both are on a mission to improve the global environmental impact of waste collection.

    Wrap Up

    The news of a low financial outlook for the upcoming financial results caused the decline in the per-share price of the HYZN stock. In order to understand future growth, investors need to do technical and fundamental analysis for better intuition.

  • Why Splash Beverage Group, Inc. (SBEV) stock is soaring today?

    Why Splash Beverage Group, Inc. (SBEV) stock is soaring today?

    Shares of the Splash Beverage Group, Inc. (SBEV) stock were soaring in the current market trading session today on January 11, 2022. SBEV stock price saw an uptrend of 57.01% to reach $1.68 a share at the time of this writing. The trading volume on the last check was 45,815,230, far higher than the average trading volume. Lets’ deep dive to understand the reason behind this bull.

    What’s Happening?

    SBEV stock became bullish after the company announced that it has got authorization to sell its TapouT performance drink in Florida. The company will initiate the selling with 47 Walmart stores that are in major metropolitan regions. In Florida, Walmart has 341 stores, the second-largest number by the state in the United States. Walmart authorization is an important milestone for the company and a good start to the year 2022. Walmart is very selective in choosing the brand to offer their shoppers. The selection of TapouT is the validation that this band can compete with the biggest brands across the world. The shareholders of the SBEV stock are happy and responding positively to this news.

    Previous News of SBEV stock

    On January 5, 2022, the company announced that its design agency won the award of Graphic Design USA for a packaging design for its TapouT performance hydration-recovery drink. The design agency has won the award among 11,000 competitors.  The design communicated the lifestyle position of the TapouT and the unique functional benefits of the performance drink over other sports drinks.

    Financial View of the SBEV stock

    • According to third-quarter 2021 financial results, the company generated $2,827,393 in revenue. This represents a whopping increase of $2,134,419 or 308% as compared to $692,974 revenue in the same period of the previous year.
    • The company reported $8,254,078 in revenue in the first nine months of 2021. This represents a $7,036,369 or 578% increase from the same tenure of the previous year.
    • Loss from the continuing operations in the third quarter of 2021 was $12.2 million for the SBEV stock. $8.8 million consisted of non-cash transactions.
    • Loss from continuing operations reached $23.2 million in the first nine months of 2021. $13.3 million loss resulted from the non-cash transactions.

    Conclusion

    The recent development of the company has made the SBEV stock bullish in the current market today. In the past six months, the stock has lost 50.14%.

  • Black Diamond Therapeutics, Inc. (BDTX) stock Rises in Premarket: Here’s to know

    Black Diamond Therapeutics, Inc. (BDTX) stock Rises in Premarket: Here’s to know

    Shares of the Black Diamond Therapeutics, Inc. (BDTX) stock were rising in the current market trading session today on January 11, 2022. BDTX stock price saw a push of 12.00% to reach $5.04 a share at the time of this writing. The stock was red in the previous trade and went down by 11.76% at closing. Let’s dig in to explore more about it.

    What’s Happening?

    BDTX stock became bullish after the announcement of clearance of investigational new drug (IND) application by the U.S Food and Drug Administration. FDA has cleared the IND for the Black Diamond’s Master Key inhibitor BDTX-1535. The Phase 1 study is expected to begin in the first quarter of 2022. The company will provide the clinical update on the second of 2023.

    FDA allowance for Black Diamond’s IND is an important milestone for the company and good news for shareholders of BDTX stock. The company is on a mission to mature its MasterKey therapies pipeline. The management is optimistic that the BDTX-1535 will address the unmet needs of the EGFR mutant GBM and NSCLC.

    BDTX Stock: Milestones

    • For the Phase 2 dose in 2022, the company has decided to collect more clinical data for the BDTX-189 safety expansion cohor This will help the company in the future development of the BDTX-189 program. For this purpose, the company will enroll additional patients. BDTX will provide further guidance for the BDTX-189 program this year.
    • Black Diamond anticipates the beginning of IND-enabling studies for the BRAF this year. About 190,000 patients suffering from solid tumors get treatment with BRAF oncogenic mutations annually.
    • By the end of 2021, Black Diamond had $210 million in cash, cash equivalents, and investments. The company believes that it has sufficient funds to finance its operating and capital expenditures.

    Financial View of BDTX stock

    Black Diamond used $26.5 million net cash for operations in the third quarter of 2021. Net cash for operations was $11.5 million in the same period of the previous year. Research and development expenses of the BDTX stock were $27.6 million in the recently reported quarter. These expenses significantly increased as compared to $12.9 million in the same tenure of the previous year. General and administrative expenses of the company were $7.7 million, higher than these expenses in the previous year. The company ended the quarter with $235.0 million in cash, cash equivalents, and investments.

    Wrap Up

    Investors are responding positively to the recent news of the BDTX stock today. The financial results reflect that the company is progressing in terms of its operations.

  • Why OneSmart International Education Group Limited (ONE) stock rose in premarket?

    Why OneSmart International Education Group Limited (ONE) stock rose in premarket?

    Shares of the OneSmart International Education Group Limited (ONE) stock were rising in the premarket trading session today on January 11, 2022. ONE stock price saw a surge of 33.38% to reach $0.25 a share at the time of this writing. The stock was gloomy in the previous trade and went down by 33.09% at closing. Let’s take a closer look at this stock to understand the reason for this bull.

    What’s Happening?

    One stock is hot among investors in the social media platforms like Reddit, Stock Twits. The stock declined in the previous trade after the news appeared that the company received the notification from NYSE concerning Delayed Form 20-F Filing. The company did not file its Annual Report on Form 20-F for the year ended August 31, 2021, timely due to which it is not in compliance with Section 802.01E of the NYSE Listed Company Manual.

    OneSmart had to file the 2021 Form 20-F by the end of December 2021. The company delayed Form 20-F due to a change in its independent registered public accounting firm for the fiscal year 2021 ended August 31. The company is striving hard to fill the form as soon as possible. This news resulted in a decline in the per-share price of ONE stock which then recovered today due to the Reddit rally. Moreover, notice which company received does not impact the listing of its ADSs.

    Previous Event of ONE stock

    On October 12, 2021, the company announced that its board of directors approved the suspension of all the educational programs and learning centers in China. The suspension of educational programs and learning centers was due to strict educational policies by the Chinese Government. Moreover, the company was facing operational difficulties in such areas. OneSmart also reported the resignations of Liang (Mason) Xu and Yan Gong from the board.

    Financial View of ONE stock

    According to the financial results for the second quarter of fiscal 2021, the company generated RMB931.6 million in revenue. This represents an increase of 5.2% from the same quarter of last year. Operating costs of the company reached RMB1,042.0 million, higher than prior-year same quarter’s operating costs. The Operating loss in the reported quarter reached RMB110.4 million, compared to RMB54.8 million in the same tenure of the previous year. Operating margin was -11.8% in the second quarter of the fiscal year 2021. The company reported RMB26.1 million of net interest expense in the last reported quarter. By the end of the quarter on February 28, 2021, the company had RMB523.7 million in cash and cash equivalents.

  • Why Aehr Test Systems (AEHR) stock is gloomy today?

    Shares of the Aehr Test Systems (AEHR) stock were gloomy in the current market trading session today on January 10, 2022. AEHR stock price saw a downtrend of11.80% to drop at $14.19 a share at the time of this writing. The stock was also down in the previous trading session and recorded a decline of 21.44% at closing. Let’s look at the culprit behind this drop.

    What’s Happening?

    Aehr Test System recently announced the second quarter of fiscal 2022 financial results on January 6, 2022. The company reported record sales in the reported quarter. Even then the AEHR stock is facing a decline in the stock market. Actually, AEHR stock outperformed in 2021 as the per-share price of the stock rose more than 800%. Hence the profit takers have stepped in to start their new year with a massive profit. This resulted in the per-share decline of the AEHR stock even after the release of strong quarterly results.

    Second Quarter Fiscal 2022 Financial Results

    • In the second quarter of the fiscal year 2022, the company generated $9.6 million in net sales. This represents a whopping 471% increase from the same quarter of last year.
    • The GAAP net income of the AEHR stock was $0.03 per diluted share or $717,000 in the recently reported quarter. This compares to GAAP net loss of 2.0 million or $0.08 per diluted share in the same quarter of the previous year.
    • Non-GAAP net income in the second quarter of the fiscal year 2022 was $1.4 million, or $0.05 per diluted share for the AEHR stock. In the same tenure of the previous year, the non-GAAP net loss was $1.7 million, or $0.07 per diluted share.
    • The company reported the highest bookings of $29.1 million in the reported quarter as compared to $1.6 million in the same prior-year quarter.
    • By the end of the quarter, the company had $36.1 million in the backlog.

    Fiscal First Six Month Financial Results of AEHR stock

    In the first six months of the fiscal year 2022, the company recorded net sales of $15.3 million, 313% higher than $3.7 million in the same period of the previous year. GAAP net income in this period was $1.4 million, or $0.05 per diluted share of AEHR stock. Non-GAAP net income was $1.0 million, or $0.04 per diluted share in the first six months of the fiscal year 2022.

    Wrap Up

    Though the AEHR stock is gloomy, its financial results reflect strong growth of the company and hence it can be a good bet for investors in the long run.

  • Tilray, Inc. (TLRY) stock climbs in the Premarket: Here’s to know

    Shares of the Tilray, Inc. (TLRY) stock were climbing in the premarket trading session today on January 10, 2022. The stock became bullish after the company announced the second-quarter fiscal year 2022 financial results. TLRY stock price saw a push of 12.77% to reach $7.24 a share at the time of this writing. The stock was gloomy in the previous trade and went down by 0.31% at closing.

    Tilray, Inc is the leading cannabis lifestyle and consumer packaged goods company based in New York. TLRY stock has a market cap of $3.07 billion and a 22,847,425 average trading volume.

    Second Quarter Fiscal 2022 Financial Results

    • In the second quarter of the fiscal year 2022, the company recorded a net income of $6 million as compared to a net loss of $89 million in the same quarter of last year.
    • Net revenue in the reported quarter reached $155 million, representing an increase of 20% from the same prior-year quarter. Cannabis revenue increased 7% to reach $58.8 million and alcohol beverage revenue was $13.7 million from SweetWate The company recorded $13.8 million in wellness segment revenue from Manitoba Harvest.
    • Adjusted EBITDA of TLRY stock was $13.8 million in the reported quarter, 8% higher than the preceding previous quarter.
    • Gross profit of the company was reduced by 7% to $32.8 million in the second quarter of the fiscal year 2022. The gross margin was 43% in the cannabis segment.

    Developments of TLRY stock

    • Sweet Water on December 21, 2021, acquired Alpine Beer and Green Flash Brewing, award-winning craft-beer brands.
    • Company on December 8, 2021, acquired Breckenridge Distiller in order to strengthen its strategic position in the United States.
    • On October 26, 2021, the company signed the medical cannabis agreement in Luxembourg.
    • On October 20, 2021, TLRY signed the expanded distribution agreement with Great North Distributors for the sales of adult-use cannabis across Canada.

    From the above developments, it seems that the company is progressing concerning its operational growth which is a good sign for the shareholders of the TLRY stock. The company also reported that it has changed its name to Tilray Brands, Inc, which is the result of its evolution from Canadian LP to a global consumer packaged goods company.

    Wrap Up

    Investors are responding positively to the recent release of the second-quarter fiscal year 2022 financial results. The company has maintained its #1 market share in the cannabis market share position in Canada.

  • Xinyuan Real Estate Co., Ltd. (XIN) stock declines in premarket: Here’s Why

    Shares of the Xinyuan Real Estate Co., Ltd. (XIN) stock were declining in the premarket trading session today on January 10, 2022. XIN stock price saw a decline of 7.89% to drop at $0.70 a share at the time of this writing. The stock was green in the previous trade and went up by 25.39% at closing. Let’s take a closer look at this stock to understand the culprit behind this decline.

    What’s Happening?

    There is no press release or any announcement by the company to justify the current bearish sentiment of XIN stock. No analyst has degraded or shrank the targeted per share price of XIN stock in recent times. It seems that profit-takers have stepped in as the XIN stock reached a certain height in the previous trade. The sentiment in the social media platforms like Reddit, Stock Twits is not positive, causing the decline in the per-share price of this stock.

    Xinyuan Real Estate Co., Ltd is a Chinese company that is engaged in residential real estate development. Currently XIN stock has a market cap of $49.85 million and 251,547 average trading volume. Let’s discuss some recent events of this stock.

    Recent Events of XIN stock

    On November 26, 2021, Xinyuan Real Estate provided its update regarding the delivery of multi-site projects in 2021. In the first ten months of 2021, the company completed and delivered 12 projects, covering 1.05 million square meters in eight cities in China. The major projects are which the company delivered were in Shandong, Henan, Sichuan provinces as well as the cities of Shanghai and Tianjin.

    By the end of October 2021, the company delivered 1,789 units of Zhengzhou International New City III. This represents a total area of 164,000 square meters. The company delivered 499 households in a single day under project B of the Zhengzhou International New City III. This is the recorded delivery by the company in a single day in recent years. The location of the project is the downtown city highlands. Property amenities consist of a courtyard and top-quality property management services.

    Conclusion

    After rising in the previous trade, XIN stock moved back in today’s premarket without any obvious news. In the last six months, the stock has lost approximately 69%.In short, research of a company’s fundamentals and future growth is necessary before any decision.